![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.
Lead Product(s): Bonafide Pollen
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Relizen
Highest Development Status: Approved Product Type: Small molecule
Recipient: Bonafide Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 30, 2023